Background Elderly patients are more likely to have oestrogen receptor positive cancers that can be treated without surgery with primary endocrine therapy (PET). Few studies have sought to identify predictors of failure of PET and so the aim of this study was to evaluate treatment failures in elderly breast cancer patients treated with PET and to determine predictors of failure. Conclusions This is the largest retrospective series evaluating PET treatment failure. Clear predictors of failure have been identified, which can be used to facilitate treatment decision making. These results support previous analyses, further validating our results.
Introduction
Frailty and the burden of co-morbid disease increase with advancing age [1] , as does the incidence of breast cancer [2] . Whilst surgery is the standard initial treatment of choice for early breast cancer [3] , some elderly and frail patients with oestrogen receptor (ER) positive cancers who are considered too unfit for general anaesthesia, may be given primary endocrine therapy (PET) [4, 5] . PET has been shown to be effective in treating breast cancer [6] .
PET use has become widespread. In 2012 a UK-based questionnaire study reported that 93% of surgeons advocated the use of PET in early operable breast cancer in the elderly [7] . Whilst PET provides relatively good local control in the short term (2-3 years), it has been found to be inferior to surgery in the long term. This was shown in a Cochrane meta-analysis that showed no difference in overall survival between PET and surgery, but an inferiority of PET in local disease control [8] . However, all but one study included were unselected for oestrogen receptor (ER) status, and all used Tamoxifen which has now largely been superseded by aromatase inhibitors (AIs) [9] .
The International Society of Geriatric Oncology (SIOG) advises that PET may be considered in patients with a short life expectancy (\2 years) or unfit for surgery [10] . Frequently, clinician's decision making in allocating PET is subjective, made in a busy time-pressured outpatient clinic, with little objectivity. NHS time targets may also influence clinician's decision making [11] , as formal anaesthetic or geriatric opinions can take time.
Treatment failure on PET is potentially catastrophic for the patient. As such, patient selection is key. Difficulties in patient selection are compounded by an increasing life expectancy, with patients with multiple comorbidities being able to live longer due to improvements in geriatric and medical care [12] [13] [14] . Few studies have directly sought to analyse failure of PET. The aim of this study was to determine the failure rate of PET in the North East of England, and to identify predictors of failure.
Methods
An observational study was performed on patients with ER-positive early breast cancer treated with PET between January 2005 and December 2015. Data collection was performed retrospectively and subjects were identified from the three North East of England breast-screening units. Local breast cancer multidisciplinary team databases were used to select patients. Patients were excluded if they had inoperable or metastatic disease at presentation, or if endocrine therapy was given as neo-adjuvant treatment to downstage the tumour prior to surgery.
Tumour characteristics
Pathological information was based on needle-core biopsies on first presentation. Strength of ER status was determined by the histochemical 'quickscore' (value out of eight) [15] . HER-2 positivity was defined by immunohistochemistry or fluorescent in situ hybridization (FISH) in borderline cases [16] . The grade of the tumour was categorised 1-3 by the modified Scarff-Bloom-Richardson (SBR) criteria [17] . Lymph node involvement was recorded either from histology or cytology, and in some cases based purely on ultrasound appearances if a tissue sample was not acquired. Tumour size was based on the maximum dimensions from ultrasound.
Treatment decisions and patient characteristics
Patients were seen for diagnosis and treatment planning in the outpatient clinic, with support from the local Multidisciplinary team (MDT). Case notes and outpatient clinic letters were reviewed to determine the first choice of endocrine agent. Data on patient co-morbid disease, cognition and social circumstances were also collected. Consultation by geriatricians or anaesthetists was recorded. The use of predictive indexes which facilitate decision making were recorded, as was any additional information on other surgeries unrelated to their breast cancer following diagnosis.
Follow-up
Length of follow-up was determined by case note review. The date of diagnosis was taken from when the diagnosing histology was made available. Patients were ultimately followed up until they died, or were still under follow-up at the censor point (December 2015). Cause of death was either determined from the case notes or from the patient's general practitioner.
Outcome variables
The primary outcome measure was treatment failure. This was defined as patients either dying with uncontrolled local disease, patients dying of metastatic breast cancer (where there was only local disease on presentation), or patients requiring surgery or radiotherapy to control local progression. Time to failure was recorded either from diagnosis to death, or diagnosis to surgery or radiotherapy. Treatment was considered a success if the patient died of causes unrelated to their breast cancer and their disease was under control at that point, or if they were still alive at the time of censoring with their disease controlled.
The secondary outcome measure was disease progression. This was defined as an increase in size of tumour whilst on PET. Time to progression was recorded from diagnosis to when the tumour clinically or radiologically increased in size.
Statistical analysis
Patients still alive without treatment failure were censored at the end of follow-up at end of December 2015. Characteristics in the three groups (treatment failures, patient who died with controlled disease and patients still alive with controlled disease) were compared using the KruskalWallis test, v 2 test or Fisher's exact test, as appropriate. Where patients had bilateral disease, tumour size and characteristics were summarised using data from the largest or most advanced tumour.
The cumulative risk of death with controlled disease and risk of treatment failure was calculated with the alternate outcome treated as a competing risk. Competing risks regression models were used to identify factors associated with dying with controlled disease and with treatment failure. Results are presented as sub-hazard ratios (SHR) with 95% confidence intervals (CI).
Analysis was carried out using STATA 14IC.
Results
Data were included from 488 patients who were followed for a total of 1271 person years. Among all patients the mean follow-up was 31. 
Patient characteristics
Characteristics of included patients are summarised in Table 1 . Overall, 206 patients were still alive with their disease controlled at the end of follow-up, 219 had died with their disease controlled and 63 experienced treatment failure. Patients who died with their disease controlled were older at diagnosis (p = 0.014) and had more comorbidities (p = 0.010) than other patients. Median tumour size at diagnosis was 30 mm in those who failed treatment, compared to 25 mm in others (p = 0.038). Tumours in patients who failed treatment were also more likely to be TPM grade 3 (p \ 0.001) and almost half of the patients had lymph node involvement compared to \20% in patients without treatment failure (p \ 0.001).
Risk of treatment failure
The cumulative risks of death with disease controlled and of treatment failure are summarised in Table 2 
Predictors of treatment outcome
The associations between patient and disease characteristics and both death with disease control and hazard of treatment failure were explored with the results summarised in Table 3 . Increasing age, more comorbidities, impaired mobility, cognitive impairment and nursing home residency were all associated with dying with disease controlled. Patients who were older, with more comorbidities and less independent were more likely to die with their disease controlled.
On the other hand, tumour size, TPM grade, axilla involvement and vascular involvement were the only factors associated with treatment failure. Patients with large and more advanced disease are more likely to experience treatment failure.
Next, multivariate regression analysis was used to identify all independent predictors of dying with disease controlled and of treatment failure with the results summarised in Table 4 . Increasing age and more comorbidities were both independent predictors of dying with disease controlled. The likelihood of dying with controlled disease increased by 2% for every year increase in age (SHR = 1.02, 1.00-1.04). Younger age (SHR = 0.96, 0.94-0.99), increasing TPM grade (SHR = 3.58, 1.93-6.63) and axilla involvement were also associated with treatment failure, with patients with axilla involvement almost twice as likely to experience treatment failure (SHR = 1.93, 1.06-3.52).
Details of treatment failures are summarised in Table 5 . Of the 63 patients who experienced failure, 32 (50.8%) died with uncontrolled disease and 22 (34.9%) from breast cancer. The median time to first failure was 28 (14-41) months.
Disease progression was reported in 86 (17.6%) of patients. Of those 66 (80.5%) continued on PET, usually with a change of agent. Treatment failure was observed in 51 (59.5%) who had progressed, 18 (20.9%) had died without failure and the remaining 17 (19.8%) were still alive without failure at the end of December 2015.
Treatment planning 270 (55.3%) patients were offered surgery in the first instance.
46 (9.4%) patients were referred for an anaesthetic assessment as part of their treatment planning. 5 (1%) patients had a geriatric assessment. 17 (3.4%) had a documented frailty or risk score performed by the surgeon. 14 patients had surgery following their diagnosis on unrelated problems requiring general anaesthesia, of which three were for hip or knee arthroplasty. Defined as using a walking aid or wheelchair 
Discussion
Advanced age and a higher burden of co-morbid disease are associated with dying with controlled disease. Younger patients, who tend to live longer, are more likely to experience treatment failure. Younger patients with higher histological grade, larger tumours and axillary lymph node metastases are most at risk of treatment failure.
This observational study provides the largest retrospective patient series in the literature investigating treatment failure of PET in elderly women. Previous failure rates of PET that have been published range from 12 to 84% [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] . Many of these studies included patients unselected for ER status however, and used Tamoxifen as the primary treatment. Letrozole was the predominant drug of choice in over 95% of our cohort. Whilst the superiority of AIs has been shown in the adjuvant [33] , neo-adjuvant [34] and palliative settings [35] in post-menopausal women, no randomised trial exists for comparison for use as a primary endocrine agent. However, with our comparatively low rate of treatment failure (12.9%), this suggests an advantage of Letrozole over Tamoxifen for use in PET. Our low rates of failure also suggest good clinical acumen, despite the lack of additional specialist input.
Randomised trials comparing surgery with PET identified the superiority of surgery in controlling local disease for long term, which suggested that PET could be given to good effect in the short term, but those living longer were more at risk of disease progression. However, few trials have sought to determine other factors associated with PET failure. Most recently, Layfield et al. [36] reported that high-grade disease and axillary lymph node involvement independently predicted early failure. Tumour size has also been found to be an independent predictor [23] , although this was in a cohort unselected for ER status. Our findings, in a larger cohort, not only validate these previous results but also found that histological evidence of vascular invasion [SHR 2.48 CI (1.15-5.34) p = 0.020] was significantly associated with treatment failure in univariable regression analysis. An early study associated HER-2 positivity with treatment failure [37] ; however, our results failed to show this, likely due to the low numbers in our cohort with positive HER-2 status. The International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA) [10] recommend that PET should only be offered to patients with a ''short estimated life expectancy (less than 2-3 years), who are considered unfit for surgery or who refuse surgery''. The mean time to failure in our cohort was about 30 months, with the mean time to requiring radiotherapy and surgery 26.5 and 29.7 months, respectively. On the one hand, this would support such a time frame. However, the probability of a patient at 3 years of dying of a non-breast-related cause with controlled local disease is 39%, with a 10% failure probability. This means that approximately half of patients would still be alive with controlled local disease at this point. Then, looking further ahead at 5 years, just fewer than 35% of patients would be predicted to still be alive with disease control. One could therefore argue that PET does have a role for longer term contrary to current guidance. Ultimately in clinical practice patient choice plays a crucial role.
As part of the Bridging the Age Gap in Breast Cancer Trial [38] , Morgan et al. reported that increasing age, higher levels of comorbidity, large tumour size and dependence in one or more ADL categories were strongly associated with non-surgical treatment. We found that those older, more co-morbid patients were more likely to die of non-breast cancer-related causes with their disease controlled and thus have successful treatment with PET. Interestingly larger tumour size independently predicted treatment failure in our cohort and so taking into consideration initial results by Morgan et al., if a patient is fit enough for surgery then they should be encouraged to have it.
Despite evidence that clinical judgment alone is an inaccurate measure of life expectancy [39, 40] , we could not demonstrate a difference in failure between those who had additional non-surgical clinical input and those whose decisions were made by the surgeon alone. This is because 35 few patients had allied health reviews. The low uptake of geriatric and anaesthetic involvement may reflect local service challenges, and highlight that decision making for PET is largely subjective. SIOG advises geriatric involvement in all elderly cancer treatment decision-making processes, but none of the local units involved in this study within the time frame for recruitment had routine access to specialist surgical and oncological liaison geriatricians. This may help explain why 14 patients had surgery for non-breast-related problems following their breast cancer diagnosis, including three joint replacement operations. Morgan et al. [38] acknowledged the difficulty in recruitment in trials involving the elderly [41] . Conducting a retrospective observational study such as this avoids such issues. However, there are limitations. The majority of the information gained was reliant on case records, in particular treatment decisions, documentation of comorbidities, living arrangements and mobility. There was a large degree of heterogeneity in how comprehensive clinic letters were. To account for this, nursing notes, routinely filed in the case records were also examined. Surveillance of tumours was also variable. Some patients would purely have clinical follow-up where clinical examination would assess for disease control, whereas others would use mammography and ultrasound. Much of these problems are the result of a retrospective study design, and involving breast units from three independent NHS trusts. There is a benefit however of a multi-institution study as it reflects wider practice and natural variations between units. This in turn makes the results more generalisable to other breast units.
This series has identified key factors associated with treatment failure on PET. Younger patients, with larger high-grade tumours and axillary node metastases would benefit from surgery over primary endocrine therapy. Patients with limited life expectancy can be treated with PET as it is likely that they will die from non-breast cancer-related causes. Treatment decision making in elderly patients in routine clinical practice is a challenge, particularly as not all patients fall into two distinct groups as described above. There is evidence from this series that some patients living beyond 3 years can maintain disease control for longer term, and as such adds to the difficulty in accurately advising patients as to the most appropriate treatment. Surgery has been shown to be safe with regional anaesthesia [42] , allowing increasingly frail patients greater access to surgery, and as such should be the standard of care for operable breast cancer. PET with AIs in post-menopausal women may be a viable long-term alternative in the right circumstance and in the absence of failure risk factors. A specific prognostic index to identify the likelihood of treatment failure would give more objectivity in treatment planning, allowing the clinician to counsel the patient appropriately. However, no such model is yet widely available.
